Comparative Evaluation of Bacterial Diversity and Richness in CF Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI Podhaler) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI Podhaler) and Inhaled Colistimethate

Trial Profile

Comparative Evaluation of Bacterial Diversity and Richness in CF Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI Podhaler) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI Podhaler) and Inhaled Colistimethate

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Tobramycin (Primary) ; Colistimethate sodium
  • Indications Cystic fibrosis-associated respiratory tract infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to discontinued.
    • 28 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top